Phase III data suggest sarilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) may have similar efficacy in moderate to severe rheumatoid arthritis as Actemra tocilizumab. Both are anti-interleukin-6 (IL-6) receptor (CD126) antibodies. The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) markets Actemra in IV and subcutaneous versions. Regeneron thinks sarilumab, which is given SC every other week, will be competitive based on its dosing regimen. SC Actemra was given both every week and once every other week in the Phase III program, but the recommended dosage is once every other week, followed by an increase to every week based on clinical response, in patients weighing <100 kg. Three other IL-6 blocking therapies - ALX-0061, clazakizumab and sirukumab - have shown efficacy in Phase II. Sirukumab is